The Human BACE1 Antibody products are affinity-purified IgG antibodies that recognize human BACE1 protein. The BACE1 antibodies are raised in rabbit using synthetic peptides and can be applied to Western blot (WB) and immunohistochemistry (IHC) detection as well as immunoprecipitation (IP) of human BACE1 protein.
The accumulation of amyloid beta protein in the cerebral cortex in Alzheimer's disease (AD) is one of the outcomes of the aberrant proteolytic cleavage of amyloid precursor protein (APP). Aberrant cleavage can occur due to the more than 50 different mutations that have been documented in the APP gene, and which are also associated with early-onset Alzheimer's disease.
Cleavage of APP occurs via beta- and gamma-secretase (through the amyloidogenic pathway), leading to the production of amyloid-beta and soluble APP-beta. The major beta-secretase enzyme is beta-site APP cleaving enzyme 1 (BACE1), also known as aspartyl protease 2 (ASP2), beta-secretase 1, HSPC104, KIAA1149, membrane-associated aspartic protease 2 and memapsin-2. BACE1 is a transmembrane protein that contains two aspartate residues in its active site. Elevated levels of BACE1 have been correlated with late-onset sporadic AD.